Literature DB >> 8383516

Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses.

I P Hall1.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8383516      PMCID： PMC1381482          DOI： 10.1111/j.1365-2125.1993.tb05662.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  45 in total

1.  Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.

Authors:  C Lugnier; P Schoeffter; A Le Bec; E Strouthou; J C Stoclet
Journal:  Biochem Pharmacol       Date:  1986-05-15       Impact factor: 5.858

2.  [3H]dipyridamole: a new ligand probe for brain adenosine uptake sites.

Authors:  P J Marangos; M Houston; P Montgomery
Journal:  Eur J Pharmacol       Date:  1985-11-19       Impact factor: 4.432

3.  cGMP phosphodiesterase in rod and cone outer segments of the retina.

Authors:  R L Hurwitz; A H Bunt-Milam; M L Chang; J A Beavo
Journal:  J Biol Chem       Date:  1985-01-10       Impact factor: 5.157

4.  Stereospecific binding of the antidepressant rolipram to brain protein structures.

Authors:  H H Schneider; R Schmiechen; M Brezinski; J Seidler
Journal:  Eur J Pharmacol       Date:  1986-08-07       Impact factor: 4.432

5.  Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.

Authors:  B E Jaski; M A Fifer; R F Wright; E Braunwald; W S Colucci
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

6.  Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients.

Authors:  D Kereiakes; K Chatterjee; W W Parmley; B Atherton; D Curran; A Kereiakes; R Spangenberg
Journal:  J Am Coll Cardiol       Date:  1984-11       Impact factor: 24.094

7.  Purification of two calcium/calmodulin-dependent forms of cyclic nucleotide phosphodiesterase by using conformation-specific monoclonal antibody chromatography.

Authors:  R S Hansen; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

8.  Neurotropic effects of the optical isomers of the selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo.

Authors:  H Wachtel
Journal:  J Pharm Pharmacol       Date:  1983-07       Impact factor: 3.765

9.  Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain.

Authors:  W Kehr; G Debus; R Neumeister
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

10.  Pharmacological studies with SK&F 94120, a novel positive inotropic agent with vasodilator activity.

Authors:  R W Gristwood; R J Eden; D A Owen; E M Taylor
Journal:  J Pharm Pharmacol       Date:  1986-06       Impact factor: 3.765
View more
  7 in total

Review 1.  The role of cAMP regulation in controlling inflammation.

Authors:  A R Moore; D A Willoughby
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

Review 2.  Phosphodiesterase inhibitors in female sexual dysfunction.

Authors:  Margit Mayer; Christian G Stief; Michael C Truss; Stefan Uckert
Journal:  World J Urol       Date:  2005-10-25       Impact factor: 4.226

3.  Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme.

Authors:  P M Silva; A C Alves; M F Serra; A L Pires; J P Silva; E O Barreto; R S Cordeiro; P J Jose; M M Teixeira; V Lagente; M A Martins
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

4.  Effect of sildenafil citrate on interleukin-1beta-induced nitric oxide synthesis and iNOS expression in SW982 cells.

Authors:  Kyung-Ok Kim; Shin-Young Park; Chang-Woo Han; Hyun Kee Chung; Dae-Hyun Yoo; Dae-Hyun Ryu; Joong-Soo Han
Journal:  Exp Mol Med       Date:  2008-06-30       Impact factor: 8.718

5.  Use of a yeast expression system for the isolation and analysis of drug-resistant mutants of a mammalian phosphodiesterase.

Authors:  R Pillai; K Kytle; A Reyes; J Colicelli
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

Review 6.  Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.

Authors:  Serap Gur; Philip J Kadowitz; Wayne J G Hellstrom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Metabolic effects of newly synthesized phosphodiesterase-3 inhibitor 6-[4-(4-methylpiperidin-1-yl)-4-oxobutoxy]-4-methylquinolin-2(1H)-one on rat adipocytes.

Authors:  Bagher Alinejad; Reza Shafiee-Nick; Hamid Sadeghian; Ahmad Ghorbani
Journal:  Daru       Date:  2015-02-21       Impact factor: 3.117
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.